STATUS OF THE CLAIMS

- 1-33. (canceled).
- 34. (new) A method of treating a disease, comprising:
 - a) providing:
 - i) a subject, wherein said subject suffers from a disease, wherein said disease comprises cells having a defective cellular energy status;
 - ii) an agent; wherein said agent reduces cellular ATP levels; and
 - b) administering said agent to said subject; wherein said agent targets said cells having a defective cellular energy status.
- 35. (new) The method of Claim 34, wherein said agent is rapamycin.
- 36. (new) The method of Claim 34, wherein said agent is a hexokinase inhibitor
- 37. (new) The method of Claim 34, wherein said agent is 2-deoxy-glucose.
- 38. (new) The method of Claim 34, wherein said agent is a PKC inhibitor.
- 39. (new) The method of Claim 34, wherein said agent is Rottlerin.
- 40. (new) The method of Claim 34, wherein said agent is 5-aminoimidazole-4-carboxyamide ribonucleotide.
- 41. (new) The method of Claim 34, wherein said agent is mitochondrial uncoupler FCCP.
- 42. (new) The method of Claim 34, wherein said defective cellular energy status is caused by a mutation in the lkb-1 gene.

- 43. (new) The method of Claim 34, wherein said defective cellular energy status is caused by a defective element of the cellular energy pathway, wherein said defective element is AMPK.
- 44. (new) The method of Claim 34, wherein said defective cellular energy status is caused by a defective element of the cellular energy pathway, wherein said defective element is TSC2.
- 45. (new) The method of Claim 34, wherein said defective cellular energy status is caused by a defective element of the cellular energy pathway, wherein said defective element is mTOR.
- 46. (new) The method of Claim 34, wherein said disease is complications associated with type 1 diabetes mellitus.
- 47. (new) The method of Claim 34, wherein said disease is complications associated with type 2 diabetes mellitus.
- 48. (new) The method of Claim 34, wherein said disease is complications associated with complications associated with metabolic syndrome.
- 49. (new) The method of Claim 47, wherein said complications associated with type 2 diabetes mellitus comprise renal dysfunction.
- 50. (new) The method of Claim 46, wherein said complications associated with type 1 diabetes mellitus comprise renal dysfunction.